Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 245 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "BRCA" Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

NCT02253251
View directory record Official record
Conditions
Cancer
Interventions
KRAS-variant and microRNA binding site mutation testing
Genetic
Lead sponsor
MiraKind
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 23, 2026, 7:04 AM EDT
Active, not recruiting Early Phase 1 Interventional

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

NCT03943173
View directory record Official record
Conditions
BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Chemotherapy, Olaparib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

NCT03511690
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
BRCA-Gist
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Alexandria, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 23, 2026, 7:04 AM EDT
Completed No phase listed Observational

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

NCT00043472
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years to 100 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 3 Interventional

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

NCT00685256
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions
counseling intervention, educational intervention, survey administration, psychosocial assessment and care, supportive care
Other · Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
8 Years to 120 Years · Female only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

NCT01989546
View directory record Official record
Conditions
Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
Interventions
BMN 673
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Jul 23, 2026, 7:04 AM EDT
Not listed No phase listed Observational

Women At Risk: The High Risk Breast Cancer Program

NCT01034891
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

NCT01803282
View directory record Official record
Conditions
Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer
Interventions
Andecaliximab, Gemcitabine, Nab-paclitaxel, Carboplatin, Pemetrexed, Leucovorin, Oxaliplatin, 5-FU, Bevacizumab, Irinotecan, Paclitaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Jul 23, 2026, 7:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

4R for Guideline Indicated BRCA Testing of Breast Center Patients

NCT01320540
View directory record Official record
Conditions
Newly Diagnosed Carcinoma of Breast, Genetic Predisposition to Disease
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Not applicable Interventional

Genetic Counseling for Breast Cancer Survivors (GC for BC)

NCT02451735
View directory record Official record
Conditions
Breast Cancer
Interventions
Video and Booklet, Factsheet
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

NCT01078662
View directory record Official record
Conditions
Ovarian, Breast, Prostate, Pancreatic, Advanced Tumours
Interventions
olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
2
States / cities
West Hollywood, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 7:04 AM EDT
Active, not recruiting Not applicable Interventional

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 7:04 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

NCT02985658
View directory record Official record
Conditions
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
Interventions
Veliparib, Cisplatin, Vinorelbine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 23, 2026, 7:04 AM EDT
Terminated Phase 2 Interventional Results available

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes

NCT03432897
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Olaparib Pill, Prostatectomy
Drug · Procedure
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 23, 2026, 7:04 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

NCT05498155
View directory record Official record
Conditions
Breast Cancer
Interventions
Neoadjuvant Olaparib monotherapy group, Neoadjuvant combination therapy with olaparib plus durvalumab
Drug · Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Greeley, Colorado • Loveland, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 7:04 AM EDT
Recruiting No phase listed Observational

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

NCT06888388
View directory record Official record
Conditions
Breast Cancer Surgery
Interventions
Nipple Sparing Mastectomy (NSM), Skin-Sparing Mastectomy (SSM), Total (Simple) Mastectomy
Procedure
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
4,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 23, 2026, 7:04 AM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

NCT02163694
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
56
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 23, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

NCT02975934
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jul 23, 2026, 7:04 AM EDT
Recruiting Phase 1 Interventional

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

NCT03968406
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Vaginal Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Radiation Therapy, Talazoparib
Other · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 23, 2026, 7:04 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

NCT02561832
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Carboplatin, Anthracycline, Cyclophosphamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
New York, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Jul 23, 2026, 7:04 AM EDT
Completed No phase listed Observational

A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

NCT05775549
View directory record Official record
Conditions
Advanced Ovarian Cancer
Interventions
None (Observational Study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
7
States / cities
Tampa, Florida • Shreveport, Louisiana • Annapolis, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jul 23, 2026, 7:04 AM EDT
Completed No phase listed Observational

International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study

NCT03078036
View directory record Official record
Conditions
Breast Cancer
Interventions
Germline BRCA Test (blood), FoundationOne Dx Genomic Profile (archival Tumour Specimen), Follow-up
Genetic · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Santa Barbara, California • Denver, Colorado • Hialeah, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Jul 23, 2026, 7:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer of the Pancreas Screening Study (CAPS 3)

NCT00438906
View directory record Official record
Conditions
Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions
Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Jul 23, 2026, 7:04 AM EDT